Investors’ shareholding will increase after receiving bonus shares. Although the share price may drop slightly, the total value of their investment will mostly remain the same.
The bonus shares will have a face value of ₹5, just like the existing shares. These bonus shares will be equal in number to the current holdings – fully paid-up and carrying all rights.
This update has been shared with both BSE and NSE. The company’s NSE code is ANUHPHR, and the BSE code is 506260.
Bonus for Demat Holders:
Investors holding shares in demat form through NSDL or CDSL will automatically receive bonus shares in their demat accounts. This bonus issue shows the company’s growth and its intent to reward shareholders. If you have invested in this company, don’t forget the record date – July 15.
About ANUH PHARMA LIMITED:
ANUH PHARMA LIMITED is an Indian pharmaceutical company that mainly produces Active Pharmaceutical Ingredients (APIs), which are the raw chemicals used to make medicines. The company was established in 1960 by late freedom fighter Shri Jaywantrai Ji Shah.
ANUH PHARMA manufactures the key chemical components that make medicines effective. For instance, the active ingredient in a fever medicine like Paracetamol is known as an API.
The company exports its APIs to countries like the USA, Europe, Latin America, the Middle East, Asia, and also serves the Indian market.
It focuses on making APIs for medicines related to antibiotics, anti-malarial, cardiovascular, and anti-tuberculosis treatments.
The company has a manufacturing unit in Maharashtra, certified with international standards such as WHO-GMP (World Health Organization – Good Manufacturing Practices) and EDQM (European Directorate for the Quality of Medicines).
